These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Verbeke L; Farre R; Trebicka J; Komuta M; Roskams T; Klein S; Elst IV; Windmolders P; Vanuytsel T; Nevens F; Laleman W Hepatology; 2014 Jun; 59(6):2286-98. PubMed ID: 24259407 [TBL] [Abstract][Full Text] [Related]
24. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Fallowfield JA; Hayden AL; Snowdon VK; Aucott RL; Stutchfield BM; Mole DJ; Pellicoro A; Gordon-Walker TT; Henke A; Schrader J; Trivedi PJ; Princivalle M; Forbes SJ; Collins JE; Iredale JP Hepatology; 2014 Apr; 59(4):1492-504. PubMed ID: 23873655 [TBL] [Abstract][Full Text] [Related]
25. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis. Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087 [TBL] [Abstract][Full Text] [Related]
26. Pien-Tze-Huang ameliorates hepatic fibrosis via suppressing NF-κB pathway and promoting HSC apoptosis. Zheng H; Wang X; Zhang Y; Chen L; Hua L; Xu W J Ethnopharmacol; 2019 Nov; 244():111856. PubMed ID: 30959141 [TBL] [Abstract][Full Text] [Related]
27. Sauchinone attenuates liver fibrosis and hepatic stellate cell activation through TGF-β/Smad signaling pathway. Lee JH; Jang EJ; Seo HL; Ku SK; Lee JR; Shin SS; Park SD; Kim SC; Kim YW Chem Biol Interact; 2014 Dec; 224():58-67. PubMed ID: 25451574 [TBL] [Abstract][Full Text] [Related]
28. Moniliformediquinone as a potential therapeutic agent, inactivation of hepatic stellate cell and inhibition of liver fibrosis in vivo. Tseng TH; Lin WL; Chen ZH; Lee YJ; Shie MS; Lee KF; Shen CH; Kuo HC J Transl Med; 2016 Sep; 14(1):263. PubMed ID: 27612633 [TBL] [Abstract][Full Text] [Related]
29. Thymosin β4 suppresses CCl Li H; Li Q; Zhang X; Zheng X; Zhang Q; Hao Z J Gene Med; 2018 Sep; 20(9):e3043. PubMed ID: 29972714 [TBL] [Abstract][Full Text] [Related]
30. Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt. Deng G; Huang XJ; Luo HW; Huang FZ; Liu XY; Wang YH World J Gastroenterol; 2013; 19(43):7778-87. PubMed ID: 24431897 [TBL] [Abstract][Full Text] [Related]
31. Raspberry Ketone Attenuates Hepatic Fibrogenesis and Inflammation via Regulating the Crosstalk of FXR and PGC-1α Signaling. Jiang YC; Dou JY; Xuan MY; Gao C; Li ZX; Lian LH; Cui ZY; Nan JX; Wu YL J Agric Food Chem; 2024 Jul; 72(28):15740-15754. PubMed ID: 38970822 [TBL] [Abstract][Full Text] [Related]
32. SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts. Renga B; Mencarelli A; Migliorati M; Cipriani S; D'Amore C; Distrutti E; Fiorucci S Inflamm Res; 2011 Jun; 60(6):577-87. PubMed ID: 21279417 [TBL] [Abstract][Full Text] [Related]
33. Stephania tetrandra prevents and regresses liver fibrosis induced by carbon tetrachloride in rats. Chor JS; Yu J; Chan KK; Go YY; Sung JJ J Gastroenterol Hepatol; 2009 May; 24(5):853-9. PubMed ID: 19220659 [TBL] [Abstract][Full Text] [Related]
34. Docosahexaenoic acid inhibits hepatic stellate cell activation to attenuate liver fibrosis in a PPARγ-dependent manner. He J; Hong B; Bian M; Jin H; Chen J; Shao J; Zhang F; Zheng S Int Immunopharmacol; 2019 Oct; 75():105816. PubMed ID: 31437794 [TBL] [Abstract][Full Text] [Related]
35. Metformin attenuates motility, contraction, and fibrogenic response of hepatic stellate cells Li Z; Ding Q; Ling LP; Wu Y; Meng DX; Li X; Zhang CQ World J Gastroenterol; 2018 Feb; 24(7):819-832. PubMed ID: 29467552 [TBL] [Abstract][Full Text] [Related]
36. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl Zhang R; Chen J; Liu D; Wang Y Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806 [TBL] [Abstract][Full Text] [Related]
37. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis. Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159 [TBL] [Abstract][Full Text] [Related]
38. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model. Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324 [TBL] [Abstract][Full Text] [Related]
39. Selective inhibition of activated stellate cells and protection from carbon tetrachloride-induced liver injury in rats by a new PPARgamma agonist KR62776. Bae MA; Rhee SD; Jung WH; Ahn JH; Song BJ; Cheon HG Arch Pharm Res; 2010 Mar; 33(3):433-42. PubMed ID: 20361309 [TBL] [Abstract][Full Text] [Related]
40. LncRNA-H19 induces hepatic stellate cell activation via upregulating alcohol dehydrogenase III-mediated retinoic acid signals. Wang ZM; Xia SW; Zhang T; Wang ZY; Yang X; Kai J; Cheng XD; Shao JJ; Tan SZ; Chen AP; Wang SJ; Zhang F; Zhang ZL; Zheng SZ Int Immunopharmacol; 2020 Jul; 84():106470. PubMed ID: 32304991 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]